Go to
current issue
-
Experts aim to boost gynaecological cancer research in Australia and beyond Lancet Oncol. (IF 41.6) Pub Date : 2025-04-17 Tony Kirby
No Abstract
-
WHO reports health service disruptions due to suspensions of aid Lancet Oncol. (IF 41.6) Pub Date : 2025-04-17 Sharmila Devi
No Abstract
-
US National Firefighter Registry for Cancer shuts down amid layoffs Lancet Oncol. (IF 41.6) Pub Date : 2025-04-17 Karl Gruber
No Abstract
-
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial Lancet Oncol. (IF 41.6) Pub Date : 2025-04-15 Mahrukh M Syeda, Georgina V Long, James Garrett, Victoria Atkinson, Mario Santinami, Dirk Schadendorf, Axel Hauschild, Michael Millward, Mario Mandala, Vanna Chiarion-Sileni, Michael Smylie, Georgy M Manikhas, Reinhard Dummer, Jennifer M Wiggins, Saim Ali, Sachin Bajirao Adnaik, Monique Tan, Maya Dajee, David Polsky
BackgroundCell-free, circulating tumour DNA (ctDNA) is an established measure of minimal residual disease; however, it is not utilised in melanoma management. We investigated whether ctDNA measurements could predict survival outcomes during adjuvant targeted therapy or placebo treatment in stage III melanoma, thereby identifying patients at high risk and low risk of recurrence. MethodsAnalytically
-
Circulating tumour DNA and melanoma: time to take the leap? Lancet Oncol. (IF 41.6) Pub Date : 2025-04-15 Saskia M Wilting, Astrid AM van der Veldt
No Abstract
-
Living within our means: trouble ahead for England's cancer planning Lancet Oncol. (IF 41.6) Pub Date : 2025-04-14 Mark Lawler, Pat Price, Richard Sullivan
No Abstract
-
Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directions Lancet Oncol. (IF 41.6) Pub Date : 2025-04-14 Francesco Pignatti, Peter Mol, Chantal Quinten, Douwe Postmus, Anja Schiel, Maxime Sasseville, Shun Tezuka, Vishal Bhatnagar, Paul Kluetz
No Abstract
-
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop Lancet Oncol. (IF 41.6) Pub Date : 2025-04-14 Madeline Pe, Caroline Voltz-Girolt, Jill Bell, Vishal Bhatnagar, Jan Bogaerts, Christopher Booth, Juan Garcia Burgos, Joseph C Cappelleri, Corneel Coens, Pierre Demolis, Harald Enzmann, Johannes M Giesinger, Alexandra Gilbert, Mogens Groenvold, Paul Kluetz, Claire Piccinin, Douwe Postmus, Chantal Quinten, Bettina Ryll, Maxime Sasseville, Peter Mol
Section snippets Well-defined PRO research objectivesA commonly shared view across various international stakeholders was that PROs intended to provide quantitative assessment of clinical outcomes should be treated like any other endpoint that is included in the evaluation of a cancer treatment. Thus, an important first step is to clearly describe the research questions that PROs can address to support
-
Belzutifan in von Hippel-Lindau disease Lancet Oncol. (IF 41.6) Pub Date : 2025-04-12 Chiara Ciccarese, Roberto Iacovelli, Giampaolo Tortora
No Abstract
-
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study Lancet Oncol. (IF 41.6) Pub Date : 2025-04-12 Ramaprasad Srinivasan, Othon Iliopoulos, Kathryn E Beckermann, Vivek Narayan, Benjamin L Maughan, Stephane Oudard, Tobias Else, Jodi K Maranchie, Ane B Iversen, Jerry Cornell, Rodolfo F Perini, Yanfang Liu, W Marston Linehan, Eric Jonasch
BackgroundHypoxia-inducible factor-2α inhibitor belzutifan is approved for von Hippel-Lindau disease-associated renal cell carcinoma, CNS haemangioblastomas, and pancreatic neuroendocrine tumours, based on previously published initial results from the LITESPARK-004 study. Updated results are presented here after a median follow-up of nearly 50 months. MethodsIn this single-arm, phase 2 study, participants
-
NHS investment boosts cancer detection for 80 000 patients Lancet Oncol. (IF 41.6) Pub Date : 2025-04-10 Elizabeth Gourd
No Abstract
-
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial Lancet Oncol. (IF 41.6) Pub Date : 2025-04-09 Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ludek Pour, Sebastian Grosicki, Andre Crepaldi, Anna Marina Liberati, Philip Campbell, Sung-Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Mai Ngo, Eva G Katz, Meletios A Dimopoulos
BackgroundIn the phase 3 ALCYONE study, the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) significantly improved outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma. Here, we present results from the final analysis of ALCYONE. MethodsALCYONE was an international, multicentre, randomised, open-label, active-controlled, phase 3 trial in adults aged
-
US funding cuts impact cancer care and research Lancet Oncol. (IF 41.6) Pub Date : 2025-04-03 Sharmila Devi
No Abstract
-
The Global Platform for Access to Childhood Cancer Medicines: addressing inequities in childhood cancer care Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 James R Downing, Tedros Adhanom Ghebreyesus
No Abstract
-
Call for a global cancer funding collaboration Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31
No Abstract
-
PARP inhibitors for prostate cancer: for whom and when? Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Matthew R Cooperberg
No Abstract
-
Sexual health and reproductive toxicity from cancer therapies Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 David J Benjamin, Mark P Lythgoe
No Abstract
-
WHO Classification of Tumours: evolution of a global resource in the molecular era Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Jennelle C Hodge, George J Netto, Bharat Rekhi, Wendy A Cooper, Michael Eden, Andrew S Field, Vicky Goh, James G Kench, Joseph D Khoury, Katia R M Leite, Zhiyong Liang, Daichi Maeda, Miguel Reyes-Múgica, Brian Rous, Aleš Ryška, Shahin Sayed, Antonia Sepulveda, Chanjuan Shi, Gary Tse, Peter Schirmacher, Dilani Lokuhetty
No Abstract
-
EUROPA trial: cost implications of radiotherapy versus endocrine therapy Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Shearwood McClelland, Ena C Oboh, Martha Khlopin, Victoria S Wu
No Abstract
-
EUROPA trial: cost implications of radiotherapy versus endocrine therapy – Authors' reply Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Icro Meattini, Lorenzo Livi, Philip M P Poortmans
No Abstract
-
Integrating dental and oral care in oncology: a crucial step towards comprehensive cancer treatment Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Emmanuelle Vigarios, Saman Warnakulasuriya, Philippe Pomar, Delphine Maret
No Abstract
-
Re-evaluating anxiety levels and participant characteristics in PATHFINDER Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Ze Xiang, Yunyang Xu, Jian Wu
No Abstract
-
Correction to Lancet Oncol 2024; 25: e205–16 Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31
Rodriguez-Otero P, Usmani S, Cohen AD, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol 2024; 25: e205–16—In this Policy Review, the spelling of author Surbhi Sidana's name was incorrect. This correction has been made as of March 31, 2025.
-
Correction to Lancet Oncol 2025; 26: 367–77 Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31
Zdenkowski N, Kuper-Hommel MJJ, Niman SM, et al. Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial. Lancet Oncol 2025; 26: 367–77—The appendix of this Article has been corrected as of March 31, 2025.
-
The impact of armed conflict on global patterns of childhood cancer Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Pamela Espinoza, Henry E Rice, Paul H Wise, Nickhill Bhakta, Alexandra Mueller, Taisiya Yakimkova, Lisa M Force, Emily R Smith, Asya Agulnik
Section snippets Incidence of cancer and related mortality in children in conflict zonesChildren living in countries with armed conflict account for an increasing proportion of global paediatric cancer deaths over the past 30 years. This pattern has resulted from both a growing number of children living in countries with conflict over time and higher cancer mortality rates in countries in conflict
-
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Nobuaki Matsubara, Arun A Azad, Neeraj Agarwal, Fred Saad, Ugo De Giorgi, Jae Young Joung, Peter C C Fong, Robert J Jones, Stefanie Zschäbitz, Jan Oldenburg, Neal D Shore, Curtis Dunshee, Joan Carles, Andre P Fay, Paul Cislo, Jane Chang, Cynthia G Healy, Alexander Niyazov, Karim Fizazi
BackgroundPatients with metastatic castration-resistant prostate cancer have poor prognoses, underscoring the need for novel therapeutic strategies. First-line talazoparib plus enzalutamide significantly improved radiographic progression-free survival compared with placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer in the phase 3 TALAPRO-2 study. We aimed to evaluate
-
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Andre P Fay, Karim Fizazi, Nobuaki Matsubara, Arun A Azad, Fred Saad, Ugo De Giorgi, Jae Young Joung, Peter C C Fong, Robert J Jones, Stefanie Zschäbitz, Jan Oldenburg, Neal D Shore, Curtis Dunshee, Joan Carles, Paul Cislo, Jane Chang, Cynthia G Healy, Alexander Niyazov, Neeraj Agarwal
BackgroundIn the phase 3 TALAPRO-2 trial, talazoparib plus enzalutamide significantly improved radiographic progression-free survival compared with placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer harbouring alterations in genes involved in homologous recombination repair (HRR). We aimed to assess patient-reported outcomes in patients with HRR-deficient metastatic
-
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Toon Van Gorp, Kathleen N Moore, Gottfried E Konecny, Alexandra Leary, Yolanda García-García, Susana Banerjee, Domenica Lorusso, Jung-Yun Lee, John W Moroney, Giuseppe Caruso, Dagmara Klasa-Mazurkiewicz, Jacqueline Tromp, Lainie P Martin, Shani Breuer, Charles A Leath, David Cibula, S John Weroha, Purificación Estévez-García, David M O’Malley, Rowan E Miller, Felix Hilpert
BackgroundMirvetuximab soravtansine-gynx (MIRV) is a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), approved by the US Food and Drug Administration for the treatment of platinum-resistant ovarian cancer in the USA. Here, we report patient-reported outcomes for participants treated with MIRV compared with investigator's choice of chemotherapy from the phase 3 MIRASOL trial
-
Innovative, early-phase clinical trials of drug–radiotherapy combinations Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Antonin Levy, Christophe Massard, Stefan Michiels, Eric Deutsch
Over the past few decades, breakthroughs in cancer biology at the molecular level have revolutionised cancer treatment. Enhanced precision in radiotherapy has not only reduced patient side-effects, but also enabled the delivery of high-dose stereotactic extracranial irradiation with unprecedented accuracy. Simultaneously, the number of medical therapies available for clinical care continues to grow
-
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Charlotte E Graham, Roser Velasco, Ana Alarcon Tomas, Orla P Stewart, Guillaume Dachy, Francesca del Bufalo, Matteo Doglio, Jan-Inge Henter, Guillermo Ortí, Zinaida Peric, Claire Roddie, Niels W C J van de Donk, Matthew J Frigault, Annalisa Ruggeri, Francesco Onida, Isabel Sánchez-Ortega, Ibrahim Yakoub-Agha, Olaf Penack
Neurological complications are an important concern in patients undergoing chimeric antigen receptor (CAR) T-cell therapy. Consensus guidelines inform the management of immune effector cell-associated neurotoxicity syndrome (ICANS). However, these guidelines are based on the early clinical experience with CD19 targeting CAR T cells in B-cell malignancies. In contrast, there are so far no published
-
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Andrew D J Pearson, Claudia Rossig, Crystal L Mackall, Nirali N Shah, André Baruchel, Sam Daems, John Anderson, Andrea Biondi, Nicholas Bird, Nicole Bodmer, Erica Brivio, Jochen Buechner, Friso G Calkoen, Todd Cooper, Teresa de Rojas, Elizabeth Fox, Rebecca Gardner, Sara Ghorashian, Delphine Heenen, Marianne Ifversen, Gilles Vassal
Realising the potentially substantial benefits of chimeric antigen receptor (CAR) T-cell therapy for children with cancer is hindered by non-scientific barriers that are also relevant for other rare diseases. A solely commercial development model will not deliver optimally due to insufficient return on investment for pharmaceutical companies. Access to therapies is restricted for patients who might
-
The National Cancer Audit Collaborating Centre (NATCAN): improving the quality of National Health Service cancer care in England and Wales Lancet Oncol. (IF 41.6) Pub Date : 2025-03-31 Ajay Aggarwal, David Cromwell, Julie Nossiter, Jan van der Meulen, Kate Walker
The National Cancer Audit Collaborating Centre (NATCAN) was launched on Oct 1, 2022, and is delivering ten national cancer audits to assess and assure the quality of National Health Service (NHS) cancer care in England and Wales. These audits are a collaboration between clinical leaders, methodological experts, professional organisations, civil society, and policy makers to develop and implement performance
-
Destruction of Gaza's only cancer specialist hospital Lancet Oncol. (IF 41.6) Pub Date : 2025-03-27 Talha Burki
No Abstract
-
Concern for cancer drugs in USA–EU tariff war Lancet Oncol. (IF 41.6) Pub Date : 2025-03-27 Sharmila Devi
No Abstract
-
Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study Lancet Oncol. (IF 41.6) Pub Date : 2025-03-25 Amyn Bhamani, Andrew Creamer, Priyam Verghese, Ruth Prendecki, Carolyn Horst, Sophie Tisi, Helen Hall, Chuen Ryan Khaw, Monica Mullin, John McCabe, Kylie Gyertson, Vicky Bowyer, Dominique Arancon, Jeannie Eng, Fanta Bojang, Claire Levermore, Anne-Marie Hacker, Esther Arthur-Darkwa, Laura Farrelly, Anant Patel, Sam M Janes
BackgroundLow-dose CT screening reduces lung cancer mortality. In advance of planned national lung cancer screening programmes, research is needed to inform policies regarding implementation. We aimed to assess the implementation of low-dose CT for lung cancer screening in a high-risk population and to validate a multicancer early detection blood test. MethodsIn this prospective, longitudinal cohort
-
Lung cancer screening implementation: turning evidence into practice Lancet Oncol. (IF 41.6) Pub Date : 2025-03-25 Marjolein A Heuvelmans
No Abstract
-
Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial Lancet Oncol. (IF 41.6) Pub Date : 2025-03-24 Eoin Dinneen, Ricardo Almeida-Magana, Tarek Al-Hammouri, Shengning Pan, Baptiste Leurent, Aiman Haider, Alex Freeman, Nicholas Roberts, Chris Brew-Graves, Jack Grierson, Rosie Clow, Norman Williams, Jon Aning, Thomas Walton, Raj Persad, Neil Oakley, Imran Ahmad, Lorenzo Dutto, Timothy Briggs, Clare Allen, Kerri Jenkins
BackgroundSparing the periprostatic neurovascular bundles during robot-assisted radical prostatectomy (RARP) improves postoperative erectile function and early urinary continence recovery. The NeuroSAFE technique, a standardised frozen section analysis, enables accurate real-time detection of positive surgical margins during nerve-sparing, increasing the likelihood of successful nerve preservation
-
Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial Lancet Oncol. (IF 41.6) Pub Date : 2025-03-23 Richard J Bryant, Ioana R Marian, Roxanne Williams, J Francisco Lopez, Claudia Mercader, Mutie Raslan, Christopher Berridge, Jessica Whitburn, Teresa Campbell, Steve Tuck, Vicki S Barber, Jessica Scaife, Aimi Hewitt, Amy Taylor, Alexander Ooms, Filipa Landeiro, Matthew Little, Jane Wolstenholme, Sukanya Ghosh, John M Reynard, Lee Unsworth
BackgroundProstate cancer diagnosis requires biopsy, traditionally performed under local anaesthetic with ultrasound guidance via a transrectal approach (TRUS). Local anaesthetic ultrasound-guided transperineal biopsy (LATP) is gaining popularity in this setting; however, there is uncertainty regarding prostate sampling, infection rates, tolerability, side-effects, and cost-effectiveness. TRANSLATE
-
Transrectal versus transperineal prostate biopsy: weighing the trade-offs Lancet Oncol. (IF 41.6) Pub Date : 2025-03-23 Badar M Mian, Kari A O Tikkinen, Adam S Kibel
No Abstract
-
Carcinogenicity of automotive gasoline and some oxygenated gasoline additives Lancet Oncol. (IF 41.6) Pub Date : 2025-03-21 Michelle C Turner, Lode Godderis, Pascal Guénel, Nancy Hopf, Betzabet Quintanilla-Vega, Sheila C Soares-Lima, Sunisa Chaiklieng, Juliana Da Silva, Silvia Fustinoni, Min Gi, Julia E Heck, François Huaux, Gunnar Johanson, Jorunn Kirkeleit, Kirill Kirsanov, Lorenzo Richiardi, João Paulo Teixeira, Andrea Terron, Jan Topinka, Mary C White, Mary K Schubauer-Berigan
No Abstract
-
Rwanda makes great strides in cancer control and treatment Lancet Oncol. (IF 41.6) Pub Date : 2025-03-20 Talha Burki
No Abstract
-
Thousands in the UK miss cancer screenings due to NHS error Lancet Oncol. (IF 41.6) Pub Date : 2025-03-20 Priya Venkatesan
No Abstract
-
Proposed US bill to reform Medicare payments for radiotherapy Lancet Oncol. (IF 41.6) Pub Date : 2025-03-20 Karl Gruber
No Abstract
-
A new war on cancer? Lancet Oncol. (IF 41.6) Pub Date : 2025-03-18 Mark Lawler, Richard Sullivan
No Abstract
-
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial Lancet Oncol. (IF 41.6) Pub Date : 2025-03-17 Berend J van der Wilk, Ben M Eyck, Bas P L Wijnhoven, Sjoerd M Lagarde, Camiel Rosman, Bo J Noordman, Maria J Valkema, Tanya M Bisseling, Peter-Paul L O Coene, Marc J van Det, Jan Willem T Dekker, Jolanda M van Dieren, Michail Doukas, Stijn van Esser, W Edward Fiets, Henk H Hartgrink, Joos Heisterkamp, I Lisanne Holster, Bastiaan Klarenbeek, David van Klaveren, Walther Jansen
BackgroundA substantial proportion of individuals with oesophageal cancer have a pathological complete response after neoadjuvant chemoradiotherapy and oesophagectomy. We aimed to investigate whether active surveillance could be an alternative for individuals with a clinical complete response after neoadjuvant chemoradiotherapy. MethodsWe performed a multicentre, stepped-wedge, cluster-randomised,
-
Non-surgical approach to operable oesophageal cancer: is it prime time yet? Lancet Oncol. (IF 41.6) Pub Date : 2025-03-17 Somnath Mukherjee
No Abstract
-
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial Lancet Oncol. (IF 41.6) Pub Date : 2025-03-17 Thomas Powles, Toni K Choueiri, Laurence Albiges, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Cristina Suarez, Pooja Ghatalia, Roberto Iacovelli, Elaine T Lam, Elena Verzoni, Mahmut Gümüş, Walter M Stadler, Christian Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, Marine Gross-Goupil, Alexandr Poprach, Maria De Santis, Mimma Rizzo, Brian Rini
BackgroundThe first-in-class hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan is approved for patients with advanced renal cell carcinoma previously treated with immune checkpoint and anti-angiogenic therapy based on results of the phase 3 LITESPARK-005 trial. We present patient-reported outcomes (PROs) from LITESPARK-005. MethodsLITESPARK-005 was an open-label, multicentre, randomised, active-controlled
-
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boosting Lancet Oncol. (IF 41.6) Pub Date : 2025-03-17 Gert De Meerleer, Kato Rans
No Abstract
-
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium Lancet Oncol. (IF 41.6) Pub Date : 2025-03-17 Amar U Kishan, Yilun Sun, Alison C Tree, Emma Hall, David Dearnaley, Charles N Catton, Himanshu R Lukka, Gregory Pond, W Robert Lee, Howard M Sandler, Felix Y Feng, Paul L Nguyen, Luca Incrocci, Wilma Heemsbergen, Floris J Pos, Eric Horwitz, Jessica Karen Wong, Karen E Hoffman, Comron Hassanzadeh, Deborah A Kuban, Daniel E Spratt
BackgroundTrials comparing moderately hypofractionated radiotherapy (MHFRT) to conventionally-fractionated radiotherapy (CFRT) for prostate cancer have varied considerably in intent (non-inferiority vs superiority) and MHFRT dose. We compare the efficacy and toxicity profiles of isodose MHFRT and dose-escalated MHFRT. MethodsThis was an individual patient data meta-analysis that identified randomised
-
Lung cancer treatment compromised by delayed genomic test results Lancet Oncol. (IF 41.6) Pub Date : 2025-03-13 Elizabeth Gourd
No Abstract
-
Internationally trained doctors in the USA Lancet Oncol. (IF 41.6) Pub Date : 2025-03-13 Sharmila Devi
No Abstract
-
Children and young people with cancer affected by disability benefit delays Lancet Oncol. (IF 41.6) Pub Date : 2025-03-06 Elizabeth Gourd
No Abstract
-
Chemical industry lobbyists will run chemical safety oversight at US EPA Lancet Oncol. (IF 41.6) Pub Date : 2025-03-06 Bryant Furlow
No Abstract
-
Projected global rise in breast cancer incidence and mortality by 2050 Lancet Oncol. (IF 41.6) Pub Date : 2025-03-06 Sharmila Devi
No Abstract
-
Personalised cancer vaccines and new regulatory struggles Lancet Oncol. (IF 41.6) Pub Date : 2025-03-03 The Lancet Oncology
No Abstract
-
Destroy or delay: hormonal therapy in oligometastatic prostate cancer Lancet Oncol. (IF 41.6) Pub Date : 2025-03-03 Amar U Kishan, Luca F Valle
No Abstract
-
Tailoring chemoimmunotherapy de-escalation in early-stage triple-negative breast cancer Lancet Oncol. (IF 41.6) Pub Date : 2025-03-03 Anthony Gonçalves, Alexandre de Nonneville
No Abstract
-
Refining multimodal strategies for locally advanced NSCLC Lancet Oncol. (IF 41.6) Pub Date : 2025-03-03 Zaoqu Liu, Long Liu, Dan Shan, Xinwei Han
No Abstract
-
Refining multimodal strategies for locally advanced NSCLC – Authors' reply Lancet Oncol. (IF 41.6) Pub Date : 2025-03-03 John H Heinzerling, Kathryn F Mileham, Myra M Robinson, Charles B Simone 2nd
No Abstract
-
Cancer care in SAARC countries Lancet Oncol. (IF 41.6) Pub Date : 2025-03-03 Maihan Abdullah
No Abstract
更新日期：2025-03-26
Copyright © 2014-2025 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号